| EPC313 | Potential end-user and community-level perspectives on new biomedical HIV prevention methods in Zimbabwe | E-poster | Other new HIV prevention tools |
| EPC314 | Considerations for the delivery of new biomedical HIV prevention methods: Zimbabwe healthcare provider perspectives | E-poster | Other new HIV prevention tools |
| EPC315 | Obstacles to using event-driven (2-1-1) PrEP: exploring the role of reported barriers on PrEP dosing choice in a national US sample | E-poster | Other new HIV prevention tools |
| EPC316 | A qualitative inquiry on potential barriers to provision and use of the PrEP ring in Kenya | E-poster | Other new HIV prevention tools |
| EPC317 | Attitudes and Beliefs regarding an HIV preventive vaccine among sexual and gender minorities in Brazil | E-poster | Other new HIV prevention tools |
| EPC318 | Acceptability of broadly neutralizing antibodies (bNAbs) for HIV prevention: a qualitative investigation among Adolescent Girls and Young Women (AGYW) in India | E-poster | Other new HIV prevention tools |
| EPC319 | Lactobacillus spp interaction with neat and formulated Griffithsin, a candidate for topical HIV prevention | E-poster | Other new HIV prevention tools |
| EPC320 | Identification of viral mutations that confer cross resistance to VRC01 antibody in HIV-1 subtype C viruses | E-poster | Other new HIV prevention tools |
| EPLBC04 | Transgender women (TGW) in HPTN 083: an evaluation of safety, efficacy, and gender affirming hormonal therapy (GAHT) interactions with long-acting cabotegravir (CAB-LA) | E-poster | Other new HIV prevention tools |
| EPLBC05 | Phase 3B, randomized, open-label, safety study of dapivirine vaginal ring and oral emtricitabine 200mg/tenofovir disoproxil fumarate 300 mg tablet in breastfeeding mother-infant pairs | E-poster | Other new HIV prevention tools |